Literature DB >> 18354184

Invariant NKT cells promote CD8+ cytotoxic T cell responses by inducing CD70 expression on dendritic cells.

Vadim Y Taraban1, Sonya Martin, Kathrine E Attfield, Martin J Glennie, Tim Elliott, Dirk Elewaut, Serge Van Calenbergh, Bruno Linclau, Aymen Al-Shamkhani.   

Abstract

Activation of invariant NK T (iNKT) cells with the glycolipid alpha-galactosylceramide promotes CD8(+) cytotoxic T cell responses, a property that has been used to enhance the efficacy of antitumor vaccines. Using chimeric mice, we now show that the adjuvant properties of iNKT cells require that CD40 triggering and Ag presentation to CD8(+) T cells occur on the same APCs. We demonstrate that injection of alpha-galactosylceramide triggers CD70 expression on splenic T cell zone dendritic cells and that this is dependent on CD40 signaling. Importantly, we show that blocking the interaction between CD70 and CD27, its costimulatory receptor on T cells, abrogates the ability of iNKT cells to promote a CD8(+) T cell response and abolishes the efficacy of alpha-GalCer as an adjuvant for antitumor vaccines. These results define a key role for CD70 in linking the innate response of iNKT cells to the activation of CD8(+) T cells.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18354184     DOI: 10.4049/jimmunol.180.7.4615

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  30 in total

1.  Interferon gamma licensing of human dendritic cells in T-helper-independent CD8+ alloimmunity.

Authors:  Roxane Lemoine; Florence Velge-Roussel; Florence Herr; Romain Felix; Hubert Nivet; Yvon Lebranchu; Christophe Baron
Journal:  Blood       Date:  2010-07-19       Impact factor: 22.113

Review 2.  Clinical development of a novel CD1d-binding NKT cell ligand as a vaccine adjuvant.

Authors:  Neal N Padte; Xiangming Li; Moriya Tsuji; Sandhya Vasan
Journal:  Clin Immunol       Date:  2010-12-24       Impact factor: 3.969

Review 3.  Harnessing invariant NKT cells in vaccination strategies.

Authors:  Vincenzo Cerundolo; Jonathan D Silk; S Hajar Masri; Mariolina Salio
Journal:  Nat Rev Immunol       Date:  2009-01       Impact factor: 53.106

Review 4.  TNF-receptor superfamily agonists as molecular adjuvants for cancer vaccines.

Authors:  Timothy Nj Bullock
Journal:  Curr Opin Immunol       Date:  2017-07-24       Impact factor: 7.486

5.  Multiple innate signaling pathways cooperate with CD40 to induce potent, CD70-dependent cellular immunity.

Authors:  Jennifer A McWilliams; Phillip J Sanchez; Catherine Haluszczak; Laurent Gapin; Ross M Kedl
Journal:  Vaccine       Date:  2009-12-06       Impact factor: 3.641

Review 6.  The immunoregulatory role of type I and type II NKT cells in cancer and other diseases.

Authors:  Masaki Terabe; Jay A Berzofsky
Journal:  Cancer Immunol Immunother       Date:  2014-01-03       Impact factor: 6.968

7.  Induction of hepatitis B virus surface antigen-specific cytotoxic T lymphocytes can be up-regulated by the inhibition of indoleamine 2, 3-dioxygenase activity.

Authors:  Hiroyasu Ito; Tatsuya Ando; Kazuki Ando; Tetsuya Ishikawa; Kuniaki Saito; Hisataka Moriwaki; Mitsuru Seishima
Journal:  Immunology       Date:  2014-08       Impact factor: 7.397

Review 8.  Glycolipid ligands of invariant natural killer T cells as vaccine adjuvants.

Authors:  Sungjune Kim; Saif Lalani; Vrajesh V Parekh; Lan Wu; Luc Van Kaer
Journal:  Expert Rev Vaccines       Date:  2008-12       Impact factor: 5.217

9.  Incorporation of NKT cell-activating glycolipids enhances immunogenicity and vaccine efficacy of Mycobacterium bovis bacillus Calmette-Guerin.

Authors:  Manjunatha M Venkataswamy; Andres Baena; Michael F Goldberg; Gabriel Bricard; Jin S Im; John Chan; Faye Reddington; Gurdyal S Besra; William R Jacobs; Steven A Porcelli
Journal:  J Immunol       Date:  2009-08-01       Impact factor: 5.422

10.  Invariant natural killer T-cell control of type 1 diabetes: a dendritic cell genetic decision of a silver bullet or Russian roulette.

Authors:  John P Driver; Felix Scheuplein; Yi-Guang Chen; Alexandra E Grier; S Brian Wilson; David V Serreze
Journal:  Diabetes       Date:  2009-11-10       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.